Glaxosmithkline | GSK - Operating Expenses


Glaxosmithkline reported GBP6.76B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Aurora Cannabis CAD 76.28M 28.24M Jun/2026
Bausch Health Companies USD 1.95B 128M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Canopy Growth CAD 98.74M 23K Jun/2026
Corcept Therapeutics USD 225.75M 10.9M Sep/2026
Drreddys Laboratories INR 73.9B 431M Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Glaxosmithkline GBP 6.76B 1.42B Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 9.88B 325M Sep/2026
Pacira USD 1.18B 995.96M Sep/2026
Perrigo USD 961.4M 670.9M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Phibro Animal Health USD 417.67M 1.04B Sep/2026
Prestige Brands USD 213.19M 7.06M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
Supernus Pharmaceuticals USD 1.06B 31.25M Sep/2026
Takeda JPY 981.78B 36.71B Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026
Zoetis USD 3.3B 155M Sep/2026